¼«ËÙÁùºÏ²Ê

Marshall S. Baker
( out of 47 reviews )

Marshall S. Baker, MD, MBA

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-587-4700

  • Marshall Baker, MD is a surgeon-scientist with over 24 years of expertise in benign and malignant disease of the pancreas, liver, gallbladder, and bile ducts. His current clinical focus is on complex foregut oncology and hepatobiliary surgery. He recognizes that minimally invasive robotic and laparoscopic surgeries generally improve recovery and utilizes these approaches with pancreas and biliary malignancy whenever possible.

    Dr. Baker’s clinical specialties Include:

    • Appendiceal cancer
    • Bile duct cancer
    • Cholangiocarcinoma
    • Colorectal metastases
    • Cystic pancreatic neuroendocrine tumors
    • Gallbladder cancer
    • Liver cancer
    • Neuroendocrine tumor of the bowel and pancreas
    • Pancreas cancer
    • Retroperitoneal sarcoma
    • Robotic liver resection
    • Minimally invasive surgery (robotic & laparoscopic)

    Dr. Baker has had a life-long passion for education and is currently a professor of surgery in the Department of Surgery at ¼«ËÙÁùºÏ²Ê, Spencer Fox Eccles School of Medicine, and serves as the Director of Surgical Simulation and the Associate Clerkship Director. His research lab continues to refine concepts of best practice in oncology using informatics-based comparative effectiveness study.

    Dr. Baker earned his undergraduate degree from Duke University and medical degree from Dartmouth Medical School. He completed general surgery residency at Northwestern University. While at Northwestern, he pursued a three-year post-doctoral research fellowship in transplant immunology and obtained a master’s degree in business administration with a focus on health industry management and finance from the Kellogg School of Business. Following residency, he completed a clinical fellowship in advanced hepatopancreaticobiliary surgery at Indiana University Medical School.

    Dr. Baker started his clinical practice and academic career in Chicago. He served sequentially on the faculties of Northwestern University Feinberg School of Medicine, the University of Chicago Pritzker School of Medicine, and Loyola University of Chicago Stritch School of Medicine where he was promoted to full professor. During these years, he developed and was recognized for clinical expertise in minimally invasive laparoscopic and robotic approaches to foregut oncology. He had a productive clinical research lab which employed advanced analytics to evaluate clinical outcomes and cost effectiveness for different treatment approaches to foregut malignancy.

    Specialties

    Patient Rating

    4.9 /5
    ( out of 47 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    July 23, 2024
    HUNTSMAN CANCER CENTER

    Dr Baker is careful and caring about you as a patient.

    July 03, 2024
    HUNTSMAN CANCER CENTER

    A friend recommended Dr Baker. He did my surgery well.

    July 03, 2024
    HUNTSMAN CANCER CENTER

    Dr. Baker¿s knowledgeable, helpful, kind.

    June 28, 2024
    HUNTSMAN CANCER CENTER

    Excellent, 100 % I will recommend Dr Baker to everyone in need of treatment regarding tumors. I feel much better now ?

    June 20, 2024
    HUNTSMAN CANCER CENTER

    Very good at explaining the why the steps in treatment are needed.

    June 12, 2024
    HUNTSMAN CANCER CENTER

    Dr Baker, was wonderful taking time to explain to me everything, very positive, and understanding. made me feel very comfortable.

    May 25, 2024
    HUNTSMAN CANCER CENTER

    Explained in detail what remains to be done and the expected time frame. Glad he is taking care of me.

    May 24, 2024
    HUNTSMAN CANCER CENTER

    Dr. Baker was great about everything he told me and listened to me about my condition and the unknown future I have

    May 23, 2024
    HUNTSMAN CANCER CENTER

    Dr. Baker is the role model is physician excellence.

    See More Patient Comments

  • Marshall Baker, MD is a surgeon-scientist with over 24 years of expertise in benign and malignant disease of the pancreas, liver, gallbladder, and bile ducts. His current clinical focus is on complex foregut oncology and hepatobiliary surgery. He recognizes that minimally invasive robotic and laparoscopic surgeries generally improve recovery and utilizes these approaches with pancreas and biliary malignancy whenever possible.

    Dr. Baker’s clinical specialties Include:

    • Appendiceal cancer
    • Bile duct cancer
    • Cholangiocarcinoma
    • Colorectal metastases
    • Cystic pancreatic neuroendocrine tumors
    • Gallbladder cancer
    • Liver cancer
    • Neuroendocrine tumor of the bowel and pancreas
    • Pancreas cancer
    • Retroperitoneal sarcoma
    • Robotic liver resection
    • Minimally invasive surgery (robotic & laparoscopic)

    Dr. Baker has had a life-long passion for education and is currently a professor of surgery in the Department of Surgery at ¼«ËÙÁùºÏ²Ê, Spencer Fox Eccles School of Medicine, and serves as the Director of Surgical Simulation and the Associate Clerkship Director. His research lab continues to refine concepts of best practice in oncology using informatics-based comparative effectiveness study.

    Dr. Baker earned his undergraduate degree from Duke University and medical degree from Dartmouth Medical School. He completed general surgery residency at Northwestern University. While at Northwestern, he pursued a three-year post-doctoral research fellowship in transplant immunology and obtained a master’s degree in business administration with a focus on health industry management and finance from the Kellogg School of Business. Following residency, he completed a clinical fellowship in advanced hepatopancreaticobiliary surgery at Indiana University Medical School.

    Dr. Baker started his clinical practice and academic career in Chicago. He served sequentially on the faculties of Northwestern University Feinberg School of Medicine, the University of Chicago Pritzker School of Medicine, and Loyola University of Chicago Stritch School of Medicine where he was promoted to full professor. During these years, he developed and was recognized for clinical expertise in minimally invasive laparoscopic and robotic approaches to foregut oncology. He had a productive clinical research lab which employed advanced analytics to evaluate clinical outcomes and cost effectiveness for different treatment approaches to foregut malignancy.

    Board Certification and Academic Information

    Academic Departments Surgery -Primary
    Academic Divisions Surgical Oncology

    Education history

    Fellowship Hepatobiliary and Pancreatic Surgery - Indiana University Medical Center Fellow
    Surgery - Northwestern University Feinberg School of Medicine Chief Resident
    Residency Surgery - Categorical - Northwestern University Feinberg School of Medicine Resident
    Business Administration - Northwestern University Kellogg School of Management M.B.A.
    Postdoctoral Fellowship Organ Transplantation - Northwestern University Feinberg School of Medicine Postdoctoral Research Fellow
    Surgery - Categorical - Georgetown University Hospital Intern/Resident
    Professional Medical Medicine - Dartmouth Medical School M.D.
    Chemistry with Distinction - Duke University B.S.

    Selected Publications

    Journal Article

    1. Swanson J, Littau M, Tonelli C, Cohn T, Luchette FA, Abdelsattar Z, Baker MS (2022). The role of endoscopic resection in early-stage esophageal adenocarcinoma: Esophagectomy is associated with improved survival in patients presenting with clinical stage T1bN0 disease. Surgery, 173(3), 693-701. ()
    2. Roat-Shumway S, Tonelli C, Singer M, Cohn T, Luchette FA, Abdelsattar Z, Baker MS (2022). Is local excision an appropriate treatment modality in patients presenting with early-stage (cT1 N0 M0) rectal adenocarcinoma? Surgery, 173(3), 665-673. ()
    3. Tonelli CM, Cohn T, Abdelsattar Z, Luchette FA, Baker MS (2023). Association of Resident Independence With Short-term Clinical Outcome in Core General Surgery Procedures. JAMA Surg. ()
    4. Kim P, Littau M, Baker TB, Abdelsattar Z, Tonelli C, Bunn C, Kulshrestha S, Luchette FA, Scaglione S, Baker MS (2022). The benefit of liver transplant beyond Milan criteria: An analysis using the National Cancer Database. Surgery, 172(6), 1823-1828. ()
    5. Tonelli CM, Lorenzo I, Bunn C, Kulshrestha S, Cohn T, Abdelsattar Z, Luchette FA, Baker MS (2022). Are Residents Able to Perform a Laparoscopic Cholecystectomy with Acceptable Outcomes When the Attending Is Not Scrubbed? J Am Coll Surg, 235(1), 60-68. ()
    6. Kulshrestha S, Penton A, Luchette FA, Baker MS, Abdelsattar ZM (2022). Variation in Hospital Cost and 1-Year Episodes of Care after Diaphragmatic Hernia Repair. J Am Coll Surg, 235(1), 111-118. ()
    7. Tonelli CM, Lorenzo I, Bunn C, Kulshrestha S, Abdelsattar ZM, Cohn T, Luchette FA, Baker MS (2022). Contemporary Matched-Cohort Comparison of Surgical Approach to Inguinal Hernia Repair: Are Minimally Invasive Approaches Associated with Higher Rates of Recurrence? J Am Coll Surg, 235(1), 119-127. ()
    8. Kulshrestha S, Sweigert PJ, Tonelli C, Bunn C, Luchette FA, Abdelsattar ZM, Pawlik TM, Baker MS (2021). Textbook oncologic outcome in pancreaticoduodenectomy: Do regionalization efforts make sense? J Surg Oncol, 125(3), 414-424. ()
    9. Lorenzo IL, Tonelli CM, Bunn C, Kulshrestha S, Agnew SP, Cohn TD, Abdelsattar ZM, Baker MS, Luchette FA (2021). Supervised independence in elective inguinal hernia repairs performed by surgical residents is not associated with compromised short clinical outcome or rates of reoperation for recurrence. Am J Surg, 223(3), 470-474. ()
    10. Tonelli CM, Lorenzo I, Bunn C, Kulshrestha S, Agnew SP, Abdelsattar ZM, Luchette FA, Baker MS (2021). Does resident autonomy in colectomy procedures result in inferior clinical outcomes? Surgery, 171(3), 598-606. ()
    11. Littau MJ, Kim P, Kulshrestha S, Bunn C, Tonelli C, Abdelsattar ZM, Luchette FA, Baker MS (2021). Resectable intrahepatic and hilar cholangiocarcinoma: Is margin status associated with survival? Surgery, 171(3), 703-710. ()
    12. Kim P, Littau M, Baker TB, Abdelsattar Z, Tonelli C, Bunn C, Kulshrestha S, Luchette FA, Baker MS (2021). Intrahepatic cholangiocarcinoma: Is there a role for liver transplantation? Surgery, 171(3), 741-746. ()
    13. Patel DJ, Bunn C, Kulshrestha S, Tonelli C, Littau M, Kim P, Luchette F, Abdelsattar Z, Baker MS (2021). Small-sized gastrointestinal stromal tumors: Is there an association between expectant management and overall survival? Am J Surg, 223(3), 521-525. ()
    14. Littau MJ, Bunn C, Kim P, Kulshrestha S, Tonelli C, Abdelsattar ZM, Luchette FA, Baker MS (2021). Low and moderate grade retroperitoneal liposarcoma: Is adjuvant radiotherapy associated with improved survival in patients undergoing R1 resection? Am J Surg, 223(3), 527-530. ()
    15. Littau MJ, Freeman R, Vigneswaran WT, Luchette FA, Baker MS, Raad W, Abdelsattar ZM, Loyola Thoracic Outcomes Group (2022). Comparative effectiveness of stereotactic body radiation therapy versus surgery for stage I lung cancer in otherwise healthy patients: An instrumental variable analysis. JTCVS Open, 9, 249-261. ()
    16. Kulshrestha S, Vigneswaran WT, Pawlik TM, Baker MS, Luchette FA, Raad W, Abdelsattar ZM, Freeman RK, Grenda T, Lubawski J, Loyola Thoracic Outcomes Group (2021). Assessment of Textbook Outcome After Surgery for Stage I/II Non-small Cell Lung Cancer. Semin Thorac Cardiovasc Surg, 34(4), 1351-1359. ()
    17. Rogers MP, Cousin-Peterson E, Barry TM, Baker MS, Kuo PC, Janjua HM (2021). Elements of the care environment influence coronary artery bypass surgery readmission. Surg Open Sci, 7, 12-17. ()
    18. Eguia E, Sweigert PJ, Li RD, Kuo PC, Janjua H, Abood G, Baker MS (2021). Laparoscopic partial hepatectomy is cost-effective when performed in high volume centers: A five state analysis. Am J Surg, 222(3), 577-583. ()
    19. Sweigert PJ, Wang X, Eguia E, Baker MS, Kulshrestha S, Tsilimigras DI, Ejaz A, Pawlik TM (2021). Does minimally invasive pancreaticoduodenectomy increase the chance of a textbook oncologic outcome? Surgery, 170(3), 880-888. ()
    20. Littau MJ, Kulshrestha S, Bunn C, Kim P, Luchette FA, Baker MS (2021). Is positive histologic surgical margin associated with overall survival in patients with resectable gallbladder cancer? Surg Open Sci, 6, 15-20. ()
    21. Al Asadi A, Hubbs DM, Sweigert PJ, Baker MS, Kabaker AS (2020). Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma. Am J Surg, 222(1), 119-125. ()
    22. Eguia E, Aranha GV, Abood G, Godellas C, Kuo PC, Baker MS (2020). Do high-volume centers mitigate complication risk and reduce costs associated with performing pancreaticoduodenectomy in ethnic minorities? Am J Surg, 222(1), 153-158. ()
    23. Bunn C, Kulshrestha S, Di Chiaro B, Maduekwe U, Abdelsattar ZM, Baker MS, Luchette FA, Agnew S (2021). A Leg to Stand on: Trauma Center Designation and Association with Rate of Limb Salvage in Patients Suffering Severe Lower Extremity Injury. J Am Coll Surg, 233(1), 120-129.e5. ()
    24. Kulshrestha S, Janjua HM, Bunn C, Rogers M, DuCoin C, Abdelsattar ZM, Luchette FA, Kuo PC, Baker MS (2021). State-Level Examination of Clinical Outcomes and Costs for Robotic and Laparoscopic Approach to Diaphragmatic Hernia Repair. J Am Coll Surg, 233(1), 9-19.e2. ()
    25. Bunn C, Ringhouse B, Patel P, Baker M, Gonzalez R, Abdelsattar ZM, Luchette FA (2021). Trends in utilization of whole-body computed tomography in blunt trauma after MVC: Analysis of the Trauma Quality Improvement Program database. J Trauma Acute Care Surg, 90(6), 951-958. ()
    26. Eguia E, Fahmy JN, Cobb AN, Sweigert P, Aranha GV, Abood G, Kuo PC, Baker MS (2020). Non-Hispanic Blacks undergoing distal pancreatectomy have higher risk-adjusted rates of morbidity and are more likely to be high-cost outliers. Am J Surg, 221(4), 759-763. ()
    27. Sweigert PJ, Eguia E, Baker MS, Link CM, Hyer JM, Paredes AZ, Tsilimigras DI, Husain S, Pawlik TM (2020). Assessment of Cancer Center Variation in Textbook Oncologic Outcomes Following Colectomy for Adenocarcinoma. J Gastrointest Surg, 25(3), 775-785. ()
    28. Bunn C, Kulshrestha S, Boyda J, Balasubramanian N, Birch S, Karabayir I, Baker M, Luchette F, Modave F, Akbilgic O (2020). Application of machine learning to the prediction of postoperative sepsis after appendectomy. Surgery, 169(3), 671-677. ()
    29. Kulshrestha S, Bunn C, Gonzalez R, Afshar M, Luchette FA, Baker MS (2020). Unhealthy alcohol and drug use is associated with an increased length of stay and hospital cost in patients undergoing major upper gastrointestinal and pancreatic oncologic resections. Surgery, 169(3), 636-643. ()
    30. Cousin-Peterson E, Janjua HM, Barry TM, Baker MS, Kuo PC (2020). Discharge timing: Does targeting an ideal length of stay for patients undergoing colectomy impact readmissions and costs of care? Am J Surg, 221(3), 570-574. ()
    31. Littau MJ, Kulshrestha S, Bunn C, Agnew S, Sweigert P, Luchette FA, Baker MS (2020). The importance of the margin of resection and external radiation in non-lipomatous retroperitoneal sarcoma. Am J Surg, 221(3), 543-548. ()
    32. Littau MJ, Kulshrestha S, Bunn C, Agnew S, Sweigert P, Luchette FA, Baker MS (2020). The importance of the margin of resection and radiotherapy in retroperitoneal liposarcoma. Am J Surg, 221(3), 554-560. ()
    33. Patel DJ, Kulshrestha S, Bunn C, Littau M, Agnew S, Baker MS (2020). Positive microscopic surgical margins: Is there an association with survival in resected small gastrointestinal stromal tumors? Am J Surg, 221(3), 549-553. ()
    34. Kulshrestha S, Dligach D, Joyce C, Baker MS, Gonzalez R, ORourke AP, Glazer JM, Stey A, Kruser JM, Churpek MM, Afshar M (2020). Prediction of severe chest injury using natural language processing from the electronic health record. Injury, 52(2), 205-212. ()
    35. Sweigert PJ, Eguia E, Nelson MH, Bunn C, Kulshrestha S, Luchette FA, Baker MS (2020). Biliary Enteric Reconstruction After Biliary Injury: Delayed Repair Is More Costly Than Early Repair. J Surg Res, 257, 349-355. ()
    36. Kulshrestha S, Bunn C, Patel PM, Sweigert PJ, Eguia E, Pawlik TM, Baker MS (2020). Textbook oncologic outcome is associated with increased overall survival after esophagectomy. Surgery, 168(5), 953-961. ()
    37. Sweigert PJ, Chen C, Fahmy JN, Eguia E, Ban KA, deLahunta D, Peters S, Baker MS, Singer MA (2020). Association of obesity with postoperative outcomes after proctectomy. Am J Surg, 220(4), 1004-1009. ()
    38. Patel DJ, Lutfi W, Eguia E, Sweigert P, Knab L, Abood G, Baker MS (2020). Adjuvant systemic therapy for small bowel gastrointestinal stromal tumor (GIST): Is there a survival benefit after R0 resection? Surgery, 168(4), 695-700. ()
    39. Eguia E, Bunn C, Kulshrestha S, Markossian T, Durazo-Arvizu R, Baker MS, Gonzalez R, Behzadi F, Churpek M, Joyce C, Afshar M (2020). Trends, Cost, and Mortality From Sepsis After Trauma in the United States: An Evaluation of the National Inpatient Sample of Hospitalizations, 2012-2016. Crit Care Med, 48(9), 1296-1303. ()
    40. Knab LM, Varsanik M, Li R, Chen C, Pak N, Eguia E, Renz C, Terrasse W, Gauthier M, Ko C, Baker M, Parada JP, Abood G (2020). Antimicrobial susceptibility of biliary stents do not predict infectious complications after whipple. Surgery, 168(3), 457-461. ()
    41. Eguia E, Baker MS, Bechara C, Shames M, Kuo PC (2020). The Impact of the Affordable Care Act Medicaid Expansion on Vascular Surgery. Ann Vasc Surg, 66, 454-461.e1. ()
    42. Janjua H, Cousin-Peterson E, Barry TM, Kuo MC, Baker MS, Kuo PC (2020). Robotic Approach to Outpatient Inguinal Hernia Repair. J Am Coll Surg, 231(1), 61-72. ()
    43. Bajic P, Patel PM, Nelson MH, Dornbier RA, Kirshenbaum EJ, Baker MS, Farooq AV, McVary KT, Gupta GN, Bresler L (2020). Penile Prosthesis Implantation and Timing Disparities After Radical Prostatectomy: Results From a Statewide Claims Database. J Sex Med, 17(6), 1175-1181. ()
    44. Sweigert PJ, Eguia E, Janjua H, Nassoiy SP, Knab LM, Abood G, Kuo PC, Baker MS (2020). Does resection improve overall survival for intrahepatic cholangiocarcinoma with nodal metastases? Surg Open Sci, 2(3), 107-112. ()
    45. Sweigert PJ, Eguia E, Baker MS, Paredes AZ, Tsilimigras DI, Dillhoff M, Ejaz A, Cloyd J, Tsung A, Pawlik TM (2020). Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol, 121(6), 936-944. ()
    46. Nelson M, Dornbier R, Kirshenbaum E, Eguia E, Sweigert P, Baker M, Farooq A, McVary KT, Gonzalez CM, Gupta G, Bresler L (2019). Use of Surgery for Post-Prostatectomy Incontinence. J Urol, 203(4), 786-791. ()
    47. Janjua H, Cousin-Peterson E, Barry TM, Kuo MC, Baker MS, Kuo PC (2019). The paradox of the robotic approach to inguinal hernia repair in the inpatient setting. Am J Surg, 219(3), 497-501. ()
    48. Patel DJ, Lutfi W, Sweigert P, Eguia E, Abood G, Knab L, Kuo PC, Baker MS (2019). Clinically resectable acinar cell carcinoma of the pancreas: Is there a benefit to adjuvant systemic therapy? Am J Surg, 219(3), 522-526. ()
    49. Patel DJ, Lutfi W, Sweigert P, Eguia E, Abood G, Knab L, Kuo PC, Baker MS (2019). Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): Is there a survival benefit following margin negative surgical resection? Am J Surg, 219(3), 436-439. ()
    50. Eguia E, Baker MS, Chand B, Sweigert PJ, Kuo PC (2019). The impact of the affordable care act (ACA) Medicaid Expansion on access to minimally invasive surgical care. Am J Surg, 219(1), 15-20. ()
    51. Eguia E, Kuo PC, Sweigert PJ, Nelson MH, Aranha GV, Abood G, Godellas C, Baker MS (2019). The laparoscopic approach to pancreatoduodenectomy is cost neutral in very high-volume centers. Surgery, 166(6), 1027-1032. ()
    52. Eguia E, Cobb AN, Baker MS, Joyce C, Gilbert E, Gonzalez R, Afshar M, Churpek MM (2019). Risk factors for infection and evaluation of Sepsis-3 in patients with trauma. Am J Surg, 218(5), 851-857. ()
    53. Sweigert PJ, Eguia E, Nelson MH, Nassoiy SP, Knab LM, Abood G, Baker MS (2019). Total gastrectomy in patients with gastric adenocarcinoma: Is there an advantage to the minimally invasive approach? Surgery, 166(4), 623-631. ()
    54. Sweigert PJ, Eguia E, Kothari AN, Ban KA, Nelson MH, Baker MS, Singer MA (2019). Do prolonged operative times obviate the benefits associated with minimally invasive colectomy? Surgery, 166(3), 336-341. ()
    55. Eguia E, Kuo PC, Sweigert P, Nelson M, Aranha GV, Abood G, Godellas CV, Baker MS (2019). The laparoscopic approach to distal pancreatectomy is a value-added proposition for patients undergoing care in moderate-volume and high-volume centers. Surgery, 166(2), 166-171. ()
    56. Liu JB, Baker MS, Thompson VM, Kilbane EM, Pitt HA (2018). Wound protectors mitigate superficial surgical site infections after pancreatoduodenectomy. HPB (Oxford), 21(1), 121-131. ()
    57. Petrova E, Lapshyn H, Bausch D, DHaese J, Werner J, Klier T, Nssler NC, Gaedcke J, Ghadimi M, Uhl W, Belyaev O, Kantor O, Baker M, Keck T, Wellner UF, StuDoQ, Pancreas study group and members of StuDoQ, Pancreas registry of the German Society for General and Visceral Surgery DGAV (2018). Risk stratification for postoperative pancreatic fistula using the pancreatic surgery registry StuDoQ|Pancreas of the German Society for General and Visceral Surgery. Pancreatology, 19(1), 17-25. ()
    58. Suss NR, Talamonti MS, Bryan DS, Wang CH, Kuchta KM, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Murad FM, Baker MS (2018). Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Surgery, 163(5), 1047-1052. ()
    59. de W Marsh R, Talamonti MS, Baker MS, Posner M, Roggin K, Matthews J, Catenacci D, Kozloff M, Polite B, Britto M, Wang C, Kindler H (2017). Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol, 117(3), 354-362. ()
    60. Benjamin AJ, Baker TB, Talamonti MS, Bodzin AS, Schneider AB, Winschester DJ, Roggin KK, Bentrem DJ, Suss NR, Baker MS (2018). Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function. Surgery, 163(3), 582-586. ()
    61. Kantor O, Pitt HA, Talamonti MS, Roggin KK, Bentrem DJ, Prinz RA, Baker MS (2018). Minimally invasive pancreatoduodenectomy: is the incidence of clinically relevant postoperative pancreatic fistula comparable to that after open pancreatoduodenectomy? Surgery, 163(3), 587-593. ()
    62. Kantor O, Talamonti MS, Wang CH, Roggin KK, Bentrem DJ, Winchester DJ, Prinz RA, Baker MS (2017). The extent of vascular resection is associated with perioperative outcome in patients undergoing pancreaticoduodenectomy. HPB (Oxford), 20(2), 140-146. ()
    63. Liu JB, Baker TB, Suss NR, Talamonti MS, Roggin KK, Winchester DJ, Baker MS (2017). Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function. Surgery, 162(5), 1032-1039. ()
    64. Kantor O, Bryan DS, Talamonti MS, Lutfi W, Sharpe S, Winchester DJ, Prinz RA, Baker MS (2017). Laparoscopic Distal Pancreatectomy for Cancer Provides Oncologic Outcomes and Overall Survival Identical to Open Distal Pancreatectomy. J Gastrointest Surg, 21(10), 1620-1625. ()
    65. Kantor O, Talamonti MS, Pitt HA, Vollmer CM, Riall TS, Hall BL, Wang CH, Baker MS (2017). Using the NSQIP Pancreatic Demonstration Project to Derive a Modified Fistula Risk Score for Preoperative Risk Stratification in Patients Undergoing Pancreaticoduodenectomy. J Am Coll Surg, 224(5), 816-825. ()
    66. Kantor O, Talamonti MS, Sharpe S, Lutfi W, Winchester DJ, Roggin KK, Bentrem DJ, Prinz RA, Baker MS (2016). Laparoscopic pancreaticoduodenectomy for adenocarcinoma provides short-term oncologic outcomes and long-term overall survival rates similar to those for open pancreaticoduodenectomy. Am J Surg, 213(3), 512-515. ()
    67. Lutfi W, Talamonti MS, Kantor O, Wang CH, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Baker MS (2016). Neoadjuvant external beam radiation is associated with No benefit in overall survival for early stage pancreatic cancer. Am J Surg, 213(3), 521-525. ()
    68. Kantor O, Talamonti MS, Lutfi W, Wang CH, Winchester DJ, Marsh R, Prinz RA, Baker MS (2016). External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma. Surgery, 160(6), 1466-1476. ()
    69. Lutfi W, Talamonti MS, Kantor O, Wang CH, Liederbach E, Stocker SJ, Bentrem DJ, Roggin KK, Winchester DJ, Marsh R, Prinz RA, Baker MS (2016). Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery, 160(3), 714-24. ()
    70. In H, Kantor O, Sharpe SM, Baker MS, Talamonti MS, Posner MC (2016). Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Ann Surg Oncol, 23(6), 1956-62. ()
    71. Kantor O, Talamonti MS, Stocker SJ, Wang CH, Winchester DJ, Bentrem DJ, Prinz RA, Baker MS (2015). A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer. J Gastrointest Surg, 20(2), 284-92. ()
    72. Zyromski NJ, Baker MS (2015). Proceedings of the 49th Annual Pancreas Club Meeting. J Gastrointest Surg, 19(12), 2258-63. ()
    73. Sur MD, In H, Sharpe SM, Baker MS, Weichselbaum RR, Talamonti MS, Posner MC (2014). Defining the Benefit of Adjuvant Therapy Following Resection for Intrahepatic Cholangiocarcinoma. Ann Surg Oncol, 22(7), 2209-17. ()
    74. Sharpe SM, Talamonti MS, Wang CE, Prinz RA, Roggin KK, Bentrem DJ, Winchester DJ, Marsh RD, Stocker SJ, Baker MS (2015). Early National Experience with Laparoscopic Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Comparison of Laparoscopic Pancreaticoduodenectomy and Open Pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg, 221(1), 175-84. ()
    75. Sharpe SM, Talamonti MS, Wang E, Bentrem DJ, Roggin KK, Prinz RA, Marsh RD, Stocker SJ, Winchester DJ, Baker MS (2014). The laparoscopic approach to distal pancreatectomy for ductal adenocarcinoma results in shorter lengths of stay without compromising oncologic outcomes. Am J Surg, 209(3), 557-63. ()
    76. Sharpe SM, In H, Winchester DJ, Talamonti MS, Baker MS (2014). Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors. J Gastrointest Surg, 19(1), 117-23; discussion 123. ()
    77. Hayman AV, Stocker SJ, Baker MS, Bentrem DJ, Prinz RA, Marsh Rde W, Talamonti MS (2013). CA 19-9 nonproduction is associated with poor survival after resection of pancreatic adenocarcinoma. Am J Clin Oncol, 37(6), 550-4. ()
    78. Cherenfant J, Talamonti MS, Hall CR, Thurow TA, Gage MK, Stocker SJ, Lapin B, Wang E, Silverstein JC, Mangold K, Odeleye M, Kaul KL, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA (2014). Comparison of tumor markers for predicting outcomes after resection of nonfunctioning pancreatic neuroendocrine tumors. Surgery, 156(6), 1504-10; discussion 1510-1. ()
    79. Baker MS, Sherman KL, Stocker SJ, Hayman AV, Bentrem DJ, Prinz RA, Talamonti MS (2014). Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: defining quality for pancreaticoduodenectomy. J Surg Oncol, 110(4), 400-6. ()
    80. Cherenfant J, Stocker SJ, Gage MK, Du H, Thurow TA, Odeleye M, Schimpke SW, Kaul KL, Hall CR, Lamzabi I, Gattuso P, Winchester DJ, Marsh RW, Roggin KK, Bentrem DJ, Baker MS, Prinz RA, Talamonti MS (2013). Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors. Surgery, 154(4), 785-91; discussion 791-3. ()
    81. Baker MS, Sherman KL, Stocker S, Hayman AV, Bentrem DJ, Prinz RA, Talamonti MS (2012). Defining quality for distal pancreatectomy: does the laparoscopic approach protect patients from poor quality outcomes? J Gastrointest Surg, 17(2), 273-80. ()
    82. Baker MS, Bentrem DJ, Ujiki MB, Stocker S, Talamonti MS (2010). Adding days spent in readmission to the initial postoperative length of stay limits the perceived benefit of laparoscopic distal pancreatectomy when compared with open distal pancreatectomy. Am J Surg, 201(3), 295-9; discussion 299-300. ()
    83. Fronza JS, Bentrem DJ, Baker MS, Talamonti MS, Ujiki MB (2009). Laparoscopic distal pancreatectomy using radiofrequency energy. Am J Surg, 199(3), 401-4; discussion 404. ()
    84. Baker MS, Bentrem DJ, Ujiki MB, Stocker S, Talamonti MS (2009). A prospective single institution comparison of peri-operative outcomes for laparoscopic and open distal pancreatectomy. Surgery, 146(4), 635-43; discussion 643-5. ()
    85. Pitt SC, Pitt HA, Baker MS, Christians K, Touzios JG, Kiely JM, Weber SM, Wilson SD, Howard TJ, Talamonti MS, Rikkers LF (2009). Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J Gastrointest Surg, 13(9), 1692-8. ()
    86. Howard TJ, Browne JS, Zyromski NJ, Lavu H, Baker MS, Shen C, Madura JA (2008). Mechanisms of primary operative failure and results of remedial operation in patients with chronic pancreatitis. J Gastrointest Surg, 12(12), 2087-95; discussion 2095-6. ()
    87. Baker MS, Knuth JL, DeWitt J, LeBlanc J, Cramer H, Howard TJ, Schmidt CM, Lillemoe KD, Pitt HA (2007). Pancreatic cystic neuroendocrine tumors: preoperative diagnosis with endoscopic ultrasound and fine-needle immunocytology. J Gastrointest Surg, 12(3), 450-6. ()
    88. Lavu H, Knuth JL, Baker MS, Shen C, Zyromski NJ, Schmidt M, Nakeeb A, Howard TJ (2008). Middle segment pancreatectomy can be safely incorporated into a pancreatic surgeon's clinical practice. HPB (Oxford), 10(6), 491-7. ()
    89. Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD (2007). Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg, 246(4), 644-51; discussion 651-4. ()
    90. Blomeier H, Zhang X, Rives C, Brissova M, Hughes E, Baker M, Powers AC, Kaufman DB, Shea LD, Lowe WL Jr (2006). Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation. Transplantation, 82(4), 452-9. ()
    91. Chen X, Zhang X, Larson CS, Baker MS, Kaufman DB (2006). In vivo bioluminescence imaging of transplanted islets and early detection of graft rejection. Transplantation, 81(10), 1421-7. ()
    92. Leventhal JR, Sun J, Zhang J, Galili U, Chong A, Baker M, Kaufman DB, Wright JR Jr (2004). Evidence that tilapia islets do not express alpha-(1,3)gal: implications for islet xenotransplantation. Xenotransplantation, 11(3), 276-83. ()
    93. Baker MS, Chen X, Rotramel AR, Nelson JJ, Lu B, Gerard C, Kanwar Y, Kaufman DB (2003). Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. Surgery, 134(2), 126-33. ()
    94. Baker MS, Chen X, Rotramel AR, Nelson JJ, Kaufman DB (2003). Interferon regulatory factor-1 down-regulates cytokine-induced IP-10 expression in pancreatic islets. Surgery, 134(2), 134-41. ()
    95. Baker MS, Chen X, Rotramel A, Nelson J, Kaufman DB (2003). Proinflammatory cytokines induce NF-kappaB-dependent/NO-independent chemokine gene expression in MIN6 beta cells. J Surg Res, 110(1), 295-303. ()
    96. Kaufman DB, Baker MS, Chen X, Leventhal JR, Stuart FP (2002). Sequential kidney/islet transplantation using prednisone-free immunosuppression. Am J Transplant, 2(7), 674-7. ()
    97. Wu JJ, Chen X, Cao XC, Baker MS, Kaufman DB (2001). Cytokine-induced metabolic dysfunction of MIN6 beta cells is nitric oxide independent. J Surg Res, 101(2), 190-5. ()
    98. Baker MS, Chen X, Cao XC, Kaufman DB (2001). Expression of a dominant negative inhibitor of NF-kappaB protects MIN6 beta-cells from cytokine-induced apoptosis. J Surg Res, 97(2), 117-22. ()
    99. Sane DC, Baker MS (1993). Human platelets possess tyrosylprotein sulfotransferase (TPST) activity. Thromb Haemost, 69(3), 272-5. ()

    Review

    1. Liu JB, Baker MS (2016). Surgical Management of Pancreatic Neuroendocrine Tumors. [Review]. Surg Clin North Am, 96(6), 1447-1468. ()
    2. Zyromski NJ, Baker MS (2016). Summary of the 50th annual Pancreas Club meeting proceedings. [Review]. J Gastrointest Surg, 21(4), 749-754.
    3. Kantor O, Baker MS (2016). Hepatocellular Carcinoma: Surgical Management and Evolving Therapies. [Review]. Cancer Treat Res, 168, 165-83. ()
    4. Zyromski NJ, Baker MS (2015). Summary of the 49th annual Pancreas Club meeting proceedings. [Review]. J Gastrointest Surg, 19, 2258-2263.
    5. Zyromski NJ, Baker MS (2014). Summary of the 48th annual Pancreas Club meeting proceedings. [Review]. J Gastrointest Surg, 18, 1385-1390.
    6. Zyromski NJ, Baker MS (2013). Summary of the 47th annual Pancreas Club meeting proceedings. [Review]. J Gastrointest Surg, 17, 1819-1823.
    7. Zyromski NJ, Baker MS (2013). Summary of the 46th annual Pancreas Club meeting proceedings. [Review]. J Gastrointest Surg, 17, 576-80.
    8. Marsh Rde W, Alonzo M, Bajaj S, Baker M, Elton E, Farrell TA, Gore RM, Hall C, Nowak J, Roy H, Shaikh A, Talamonti MS (2012). Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part II: multidisciplinary management. [Review]. J Surg Oncol, 106(3), 339-45. ()
    9. Marsh Rde W, Alonzo M, Bajaj S, Baker M, Elton E, Farrell TA, Gore RM, Hall C, Nowak J, Roy H, Shaikh A, Talamonti MS (2012). Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology. [Review]. J Surg Oncol, 106(3), 332-8. ()
    10. Zyromski NJ, Baker MS (2012). Summary of the 45th annual Pancreas Club meeting proceedings. [Review]. J Gastrointest Surg, 16(5), 935-45. ()
    11. Abbott DE, Baker MS, Talamonti MS (2010). Neoadjuvant therapy for pancreatic cancer: a current review. [Review]. J Surg Oncol, 101(4), 315-20. ()

    Letter

    1. Kantor O, Baker MS (2018). Response to "Extrapolation of Fistula Grade from the Pancreatectomy Participant Use File of the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP)". [Letter to the editor]. Surgery, 164(5), 1126-1134. ()
    2. Baker MS, Sharpe SM, Talamonti MS, Wang E, Roggin KK, Bentrem DJ, Winchester DJ, Marsh RD, Stocker SJ (2015). The Learning Curve Is Surmountable: In Reply to Fong and colleagues. [Letter to the editor]. J Am Coll Surg, 222(2), 210-1. ()

  • News & Podcasts

    Huntsman Cancer Institute News